{
    "nct_id": "NCT05287399",
    "official_title": "An Open-Label, Multicenter, Single-Arm Phase 1 Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61 in Subjects With Advanced Solid Tumors",
    "inclusion_criteria": "* Adults â‰¥ 18 years of age at the time of screening\n* Histological or cytological diagnosis of advanced/metastatic solid tumor that is resistant to standard therapy or for which no standard therapy is available, regardless of cancer stage and previous experienced therapies\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* At least one measurable lesion, as defined by RECIST 1.1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known symptomatic brain metastases requiring steroids\n* Known history of another primary solid tumor\n* Subjects discontinued prior therapy with immune checkpoints due to toxicity if previously received therapy with this class of drugs\n* Known history of idiopathic pulmonary fibrosis, drug-induced pneumonitis, or evidence of active pneumonia or pneumonitis\n* Gastrointestinal disorders that might affect drug absorption",
    "miscellaneous_criteria": ""
}